1. Lynch DA, et al. Radiology 2018; 288:859–866;
2. Kinney GL, et al. Am J Epidemiol 2018; 187:2109–2116;
3. Young KA, et al. Chronic Obstr Pulm Dis 2019; 6:400–413.

This study was funded and sponsored by Boehringer Ingelheim. Vicki Cronin, PhD, at MediTech Media provided editorial assistance in the development of this poster, funded by Boehringer Ingelheim. The authors would like to thank all the patients for participating in this trial, and they also extend their thanks to the investigators.

JDC has nothing to disclose. AE, AG, BL, CD, FR, HK and MB are employees of Boehringer Ingelheim. DAL has received grants from NHLBI, and personal fees from Acceleron, Boehringer Ingelheim, Genentech, Parexel, Roche and Veracyte. In addition, DAL has a patent for ‘systems and methods for classifying severity of COPD’ pending. HW reports grants and personal fees from Boehringer Ingelheim, and personal fees from AstraZeneca, GSK, Chiesi, Novartis and Menarini, outside the submitted work. JV-C has received grants and personal fees from Boehringer Ingelheim and Novartis, and grants from Siemens Healthineers. AMT has received personal fees from Boehringer Ingelheim, and grants and personal fees from AstraZeneca, Chiesi, CSL Behring and Grifols Biotherapeutics. RM has received personal fees from AstraZeneca, Boehringer Ingelheim, GSK, Merck Sharp & Dohme, Mundipharma, Novartis and Roche. WJ has received grants from AstraZeneca and Chiesi. AL-S received a study fee in relation to the FOOTPRINTS® study from Boehringer Ingelheim.